One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging.
Dr. Yeo’s lab will focus on developing drug/gene delivery systems which can address these challenges in delivery. Specific research projects include: